Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Article History
Received: 19 September 2018
Accepted: 28 January 2019
First Online: 8 March 2019
Compliance with ethical standards
:
: Martin Griesshammer has received consultancy fees and honoraria from and has served on speakers bureaus for Gilead, Baxalta, AOP Orphan, Shire, and Novartis and has received honoraria from and has served on speakers bureaus for Sanofi. Jean-Jacques Kiladjian has received honoraria from and has participated in advisory boards for Novartis, AOP Orphan, and Celgene. Carlos Besses has received consultancy fees and honoraria from Novartis and has received research support from Novartis and Celgene.